Editorial note: this article summarises published research on GHK-Cu, Snap-8 and the vendor blends sold as GLOW and KLOW. Baclabs does not sell these compounds or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
GHK-Cu is the most studied cosmetic peptide and the one with the widest gap between what the literature supports and what is marketed. The tripeptide glycyl-L-histidyl-L-lysine, complexed with a copper(II) ion, has a substantial record in topical wound and photoageing research, most of it associated with Loren Pickart, who first isolated it from human plasma in 1973. Injectable GHK-Cu, by contrast, has no controlled human trials at all.
This article, part of the specialized peptides cluster, separates the three things that get bundled together under “glow peptides”: GHK-Cu itself, Snap-8 (a topical wrinkle-relaxing ingredient), and the vendor blends called GLOW and KLOW. It also answers the search for a “ghk cu hair growth protocol” with what has actually been tested, and works through the reconstitution maths for a 50 mg vial for readers using it in a research setting.
What GHK-Cu is and what it does in skin
GHK occurs naturally in plasma, saliva and urine. Pickart and Margolina’s 2018 review reports plasma concentrations of about 200 ng/mL at age 20 falling to around 80 ng/mL by 60, and frames the peptide as a signal released from damaged extracellular matrix that recruits repair processes [1]. Copper binding is part of the mechanism: the complex delivers copper to enzymes such as lysyl oxidase (collagen cross-linking) and superoxide dismutase.
The gene-expression data are the most striking part of the review. Using the Broad Institute’s Connectivity Map, GHK altered the expression of roughly 31 per cent of human genes by at least 50 per cent, increasing expression in 59 per cent of those and suppressing it in 41 per cent [1]. That breadth is also why systemic exposure at unknown doses is not a trivial proposition.
The human clinical trials are topical. The review lists a 12-week study of a GHK-Cu facial cream in 71 women showing increased skin density and thickness, reduced laxity and fewer fine lines; a 12-week eye-cream study in 41 women that outperformed placebo and vitamin K; and a thigh-skin study in which GHK-Cu improved collagen production in 70 per cent of women compared with 50 per cent for vitamin C and 40 per cent for retinoic acid [1]. An 8-week randomised trial of GHK-Cu in nano-lipid carriers reported 55.8 per cent wrinkle-volume reduction against control [1]. These are small, industry-adjacent studies, but they are real controlled human data for the topical route.
GHK-Cu hair growth protocol: what has been tested
The hair literature is older and thinner than the skin literature. Uno and Kurata (1993), working mainly on minoxidil and diazoxide in macaques, also reported that a topical copper-binding peptide (PC1031) enlarged vellus follicles on the back skin of fuzzy rats, an effect they described as similar to topical minoxidil [2]. Pyo and colleagues (2007) showed that the related tripeptide-copper complex AHK-Cu, at picomolar to nanomolar concentrations, lengthened human hair follicles ex vivo and stimulated dermal papilla cell proliferation [6]. Pickart and Margolina’s review lists increased hair growth and follicle size among GHK-Cu’s established actions but does not present clinical data for it [1], and the 2026 aesthetic dermatology reviews that cover copper peptides draw on the same animal and ex-vivo studies [4][5]. There is no adequately powered randomised trial of GHK-Cu in human hair loss, and the formulations tested were topical, at cosmetic concentrations.
So the answer to “what is the GHK-Cu hair growth protocol” is that the tested route is topical scalp application; there is no published protocol for subcutaneous GHK-Cu and hair. Minoxidil and finasteride have decades of randomised data; GHK-Cu and its analogues have a rodent study, an ex-vivo follicle study and a bullet point in a review [1][2][6].
Topical versus injectable GHK-Cu
Every controlled human result above comes from creams, serums or scalp solutions. The injectable use promoted online, whether subcutaneous for “systemic rejuvenation” or intradermal in the face, rests on extrapolation from the gene-array and animal wound data. There are no published human trials of injected GHK-Cu, no pharmacokinetic data at the doses sold, and no characterisation of what repeated copper delivery does to hepatic copper stores. Even reviewers writing for the aesthetic clinics that offer it note that GHK-Cu has no regulatory clearance for injection [5]. Vendors selling 50 mg vials for injection are supplying an unlicensed product; in the UK, presenting it for human use brings it within the Human Medicines Regulations 2012.
Snap-8: a topical cosmetic ingredient
Snap-8 is the trade name for acetyl octapeptide-3, an eight-residue extension of the hexapeptide argireline (acetyl hexapeptide-8). Both are marketed as “Botox-like” because their sequence mimics the N-terminal end of SNAP-25, one of the SNARE proteins that dock acetylcholine vesicles at the neuromuscular junction. The claim is that the peptide competes for SNARE-complex formation, reducing the strength of the contractions that fold expression lines [3].
The evidence for Snap-8 specifically is a single supplier study: 17 women applied a 10 per cent solution of the commercial ingredient (about 0.005 per cent pure peptide) twice daily for 28 days, with a reported 34.98 per cent reduction in wrinkle depth versus 27.05 per cent for argireline [3]. Argireline itself has several independent randomised trials; Snap-8 has this comparison and little else. It is an INCI-listed cosmetic ingredient designed for topical use, and there is no rationale for injecting it.
What GLOW and KLOW actually are
GLOW and KLOW are not compounds. They are names used by research-peptide vendors for blended vials, typically GHK-Cu, BPC-157 and TB-500 in a combined 70 mg vial (GLOW), with KPV added to make an 80 mg KLOW vial (compositions as stated in vendor listings; we do not link to peptide sellers). Individually, BPC-157 and TB-500 have animal data and no controlled human trials; KPV has in-vitro and rodent colitis data. No study has tested any of these combinations in people. A 70 mg vial of three peptides in unstated ratios also cannot be dosed per component with any precision. The BPC-157 and TB-500 article and the KPV article cover the individual compounds; the tanning and libido peptides often sold beside them are in the Melanotan and PT-141 article.
Reconstituting a 50 mg GHK-Cu vial
GHK-Cu is usually supplied as a blue lyophilised powder in 50 mg or 100 mg vials. The powder dissolves readily; the formula is concentration = milligrams in the vial ÷ millilitres of diluent. On a U-100 insulin syringe, 100 units = 1 mL, so one unit delivers the concentration divided by 100.
| Diluent added to 50 mg | Concentration | Per unit (U-100) | Units for 1 mg | Units for 2 mg |
|---|---|---|---|---|
| 1 mL | 50 mg/mL (50,000 mcg/mL) | 500 mcg | 2 | 4 |
| 2 mL | 25 mg/mL (25,000 mcg/mL) | 250 mcg | 4 | 8 |
| 2.5 mL | 20 mg/mL (20,000 mcg/mL) | 200 mcg | 5 | 10 |
| 5 mL | 10 mg/mL (10,000 mcg/mL) | 100 mcg | 10 | 20 |
Worked example: 50 mg + 2 mL bacteriostatic water = 25 mg/mL = 25,000 mcg/mL. Each unit on a U-100 syringe is 250 mcg, so 8 units contain 2 mg. For a topical serum the target is a percentage: 50 mg in 50 mL of base is 0.1 per cent.
A 50 mg vial reconstituted for research use will be punctured many times over days or weeks, so it needs a preserved diluent. Bacteriostatic water contains 0.9 per cent benzyl alcohol and is suitable for multi-dose use for up to 28 days after first puncture; sterile water for injection has no preservative and is single-use, as explained in bacteriostatic vs sterile water. Keep the reconstituted vial refrigerated and note the date of first puncture; the storage guide covers the 28-day rule. Baclabs supplies UK-stocked bacteriostatic water in 30 mL vials; see the reconstitution guide for the full method.
Frequently asked questions
Is GHK-Cu the same as copper peptide?
“Copper peptide” in skincare almost always means GHK-Cu, the copper complex of glycyl-L-histidyl-L-lysine. Some products use other copper-binding peptides or the Tricomin complex, so check the INCI list. Topical GHK-Cu has small controlled trials showing improved skin density and fewer fine lines over 8–12 weeks [1]; those results do not transfer to injected products.
Does GHK-Cu regrow hair?
The evidence is a 1993 rat study in which a topical copper-binding peptide enlarged follicles to a degree comparable with minoxidil [2], and a 2007 ex-vivo study in which the analogue AHK-Cu lengthened human hair follicles [6]. There is no randomised human trial. The tested route is topical scalp application; there is no published protocol for injected GHK-Cu and hair growth.
What is in a GLOW peptide blend?
GLOW is a vendor name, not a compound. It usually contains GHK-Cu, BPC-157 and TB-500 in a single 70 mg vial; KLOW adds KPV for 80 mg, according to the sellers’ own listings. No clinical study has tested these combinations, the component ratios are set by the seller, and BPC-157 and TB-500 have no controlled human trials individually.
Can Snap-8 be injected?
No. Snap-8 (acetyl octapeptide-3) is a topical cosmetic ingredient designed to reduce expression-line contraction from the skin surface, with a single 28-day supplier study behind it [3]. It has no injectable formulation, no injection safety data and no plausible reason to be injected. Lyophilised Snap-8 vials are intended for dissolving into serums.
References
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Pickart L, Margolina A. International Journal of Molecular Sciences, 2018
- Chemical agents and peptides affect hair growth. Uno H, Kurata S. Journal of Investigative Dermatology, 1993
- Acetyl Octapeptide-3 (SNAP-8): ingredient summary and supplier comparison study. INCIDecoder, accessed 2026
- Copper Peptides in Regenerative Aesthetic Dermatology. Sarbaziha R et al. Dermatological Reviews, 2026
- Copper tripeptide GHK-Cu and Regenerative Aesthetics. PRIME Journal
- The effect of tripeptide-copper complex on human hair growth in vitro. Pyo HK et al. Archives of Pharmacal Research, 2007
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.